The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The new centre brings advanced corneal procedures pioneered in India
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
Dr Agarwals Eye Hospital has reported total income of Rs. 118.40 crore during the period ended September 30, 2025
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Subscribe To Our Newsletter & Stay Updated
